Paige vs PathAI
The comparison the whole pathology lane is measured against, and it did not exist in this index until now. Paige holds the historically decisive credential, the first authorization for an AI based digital pathology product, obtained through the De Novo route, which created the regulatory category everything since has used. PathAI holds the broader current position: clearance for its image management system for primary diagnosis, a large portfolio of interpretation modules, qualification of a tool under a drug development regime that subjected the model to review almost nothing else here has faced, and a model change plan a regulator has already looked at. For a laboratory buying today, PathAI covers more of the workflow and publishes more about how the models are governed. Paige remains the reference point for what an authorised pathology algorithm looks like.
- It produced the first authorization for an AI based digital pathology product through the De Novo route, which created the regulatory category the rest of this lane now files into.
- It takes a route to accountability nothing else in this index takes, which is worth understanding directly rather than through a grade.
- Depth in prostate cancer detection is authorised rather than claimed, with foundation model scale work behind the broader ambition.
- The evidence spans regulatory, commercial and academic axes at once, including a drug development tool qualification that put a pathology model through a review process almost nothing else here has faced.
- Model change is governed by a plan a regulator has reviewed, which is a materially stronger mechanism than a published principles page.
- Both cloud and on premise deployment are offered, a certification is stated openly alongside the most substantial vulnerability disclosure programme in this lane, and the business associate position is the best stated here.
Side by Side
| Axis | P Paige |
P PathAI |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
These are the two names most pathology departments shortlist and their regulatory positions are not equivalent, so read them precisely rather than as competing claims of being first. One holds a De Novo authorization that created the category for AI cancer detection support; the other holds clearance for an image management system for primary diagnosis plus qualification of an interpretation tool under a separate regime. Those are different objects doing different jobs.
Neither publishes pricing of any kind, and neither publishes a bias evaluation or subgroup performance analysis, which in pathology matters because staining, scanner and preparation variation across laboratories affects model output before any patient variable does.